Table 5 Somatosensory evoked potentials in the study groups

Prolonged N9 latency

0 (0.0)

0 (0.0)

0 (0.0)

–

–

Decreased N9 amplitude

0 (0.0)

10 (21.3)

18 (21.7)

–

< 0.001

Prolonged N13 latency

4 (11.4)

0 (0.0)

0 (0.0)

–

0.005

Decreased N13 amplitude

0 (0.0)

7 (14.9)

4 (4.8)

–

0.018

Prolonged P14 latency

3 (8.8)

2 (4.3)

4 (4.8)

–

0.930

Prolonged N18 latency

20 (57.1)

0 (0.0)

0 (0.0)

–

< 0.001

Decreased N18 amplitude

14 (40.0)

17 (36.2)

22 (26.5)

–

0.279

Prolonged N20 latency

2 (5.7)

0 (0.0)

2 (2.4)

–

0.250

Decreased N20 amplitude

0 (0.0)

7 (14.9)

4 (4.8)

–

0.018

Prolonged P25 latency

0 (0.0)

0 (0.0)

0 (0.0)

–

–

Decreased P25 amplitude

0 (0.0)

7 (14.9)

4 (4.8)

–

0.018

Prolonged PCT

3 (8.8)

1 (2.1)

8 (9.6)

–

0.270

Prolonged CCT

3 (8.8)

2 (4.3)

7 (8.4)

–

0.642

N9 latency

9.18

9.21

8.75

9.22

0.010

N9 amplitude

5.26

6.10

6.98

6.15

0.030

N13 latency

12.19

12.13

11.73

11.95

0.137

N13 amplitude

2.27

2.37

3.16

2.88

0.223

P14 latency

13.67

13.80

13.39

13.17

0.170

P14 amplitude

1.80

2.17

1.73

2.12

0.695

N18 latency

16.69

16.94

16.50

17.17

0.117

N18 amplitude

3.12

2.53

3.70

4.70

0.001*

N20 latency

18.39

18.21

17.75

17.95

0.070

N20 amplitude

1.86

1.66

1.72

2.24

0.356

P25 latency

21.65

21.25

21.22

23.39

< 0.001**

P25 amplitude

3.88

3.58

3.90

4.43

0.600

PCT

3.01

2.91

2.97

2.73

0.467

CCT

6.20

6.09

6.03

6.00

0.882